NeoScreen®: Selecting neo-epitopes for a personalized cancer vaccine – First clinical case in progress
NeoScreen® from Immunitrack is a leading platform technology for the study of Major Histocompatibility Complex class I and class II (MHC I & II) interactions with potential tumour-specific epitopes.
Immunitrack is reporting its first case of neo-epitope selection for the treatment of a patient suffering from colorectal cancer. To our knowledge this is the first case where in-silico methods are combined with in vitro MHC/neo-epitope binding assay in a fully personalized manner – and in less than 3 weeks!
The patient is expected to be treated in May 2019.